Dako A/S announced it has entered into a master framework agreement with Eli Lilly and Company for the development of companion diagnostic tests to identify patients who may be more likely to benefit from an investigational oncology medicine currently under development by Lilly. The agreement constitutes a framework for collaboration between Dako and Lilly with a focus on the Lilly oncology pipeline.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
914.6 USD | +1.83% |
|
+1.02% | +56.89% |
07-04 | ETF of the week: Investing in strong trends with the momentum theme | ![]() |
07-03 | Health Stocks Slip in Risk-On Trade -- Health Care Roundup | DJ |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+56.89% | 823B | |
+39.52% | 627B | |
-6.55% | 353B | |
+15.99% | 320B | |
+7.92% | 295B | |
+13.74% | 239B | |
+13.83% | 220B | |
-0.49% | 219B | |
+7.94% | 167B | |
-2.57% | 159B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Dako A/S Enters Collaboration with Eli Lilly and Company for Development of Companion Diagnostics